Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic
Impairment Study confirming that the company’s lead drug candidate, the magnetic resonance imaging (MRI) contrast agent Orviglance®, is well tolerated in patients with
hepatic impairment.

Press inquiries should be adressed to: